MDCLF
MedinCell S.A.
Set alert
34.39 USD 0.00 0.00%
6.98 Day range 6.98
6.98 52-week range 34.39
- YTD
- +392.69%
- 1 year
- +392.69%
- Open
- 6.99
- Prev close
- 34.39
- Mkt cap
- 1.24B
- Vol
- 21.64K
- Avg vol
- 9
- EPS
- -1.09
- P/E
- 0.00
More statistics
- Low
- 6.98
- High
- 6.98
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jun 16, 2026 | Mar 31, 2026 | -0.25917 | -0.49493 | -0.24 | -90.97% |
| Dec 9, 2025 | Sep 30, 2025 | -0.30509 | -0.56644 | -0.26 | -85.66% |
| Jun 17, 2025 | Mar 31, 2025 | -0.45438 | -0.13327 | +0.32 | +70.67% |
| Dec 3, 2024 | Sep 30, 2024 | — | -0.54902 | — | — |
| Jun 25, 2024 | Mar 31, 2024 | — | -0.62587 | — | — |
| Dec 21, 2023 | Sep 30, 2023 | — | -0.30882 | — | — |
News
- Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan
- MedinCell S.A. (MDCLF) Discusses U.S. Approval of Weltruza and Its Impact on Schizophrenia Treatment and Financial Outlook Transcript
- Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)
- Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
- Medincell to Participate in Upcoming Investor Conferences
- Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
- Medincell Appoints Edna Venneker, MD, as Chief Medical Officer
- Medincell's Dr Grace Kim to Participate in Piper Sandler CNS Symposium
- Medincell: UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
- Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg
Your note
Sign in to keep a note on MDCLF — it syncs with the Stock Master app.